Inclusion Criteria:

• * Undergoing one of the following orthopedic shoulder surgeries:
• * Total shoulder arthroplasty
• * Reverse total shoulder arthroplasty
• * Shoulder hemiarthroplasty
• * Rotator cuff repair
• * Receiving standard anesthesia during surgery
• * If a subject is of reproductive potential, they must be on effective contraception one month prior, during treatment, and one month following treatment.

Exclusion Criteria:

• * Not between the ages of 18-55 years old
• * History of revision shoulder arthroplasty
• * History of liver disease or impairment
• * Are currently taking valproate or clobazam
• * Are currently taking a moderate/strong CYP3A4 or CYP2C19 inhibitor
• * Are currently taking a strong CYP3A4 or CYP2C19 inducer
• * Are currently taking narcotics
• * History of substance/alcohol abuse
• * Those currently or previously under the care of a pain management specialist
• * History of marijuana/cannabidiol (not including topical) regular use within the past 6 months
• * Allergy related to cannabidiol
• * Allergy related to sesame seeds
• * Pregnancy (As part of standard of care, all female participants will be administered a urine pregnancy test prior to surgery. A negative test result is required to participate in the study.)
• * If you are taking any medications with known risks for suicidal behavior and ideation
• * If you have a diagnosed psychiatric or sleeping disorder
• * If you are actively breastfeeding
• * Patients currently taking central nervous system (CNS) depressants
• * Patients currently taking other drugs with known hepatotoxicity
• * Vulnerable populations.
• Patients taking concomitant medications which are substrate of uridine 5'-diphospho-glucuronosyltransferase 1-9 (UGT1A9), uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7), CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and P-gp will be monitored for potential adverse events based on the Epidiolex® label for the concomitant medication being used.